Fresenius Medical Care AG & Co. (FMS) Rating Reiterated by DZ Bank

DZ Bank reaffirmed their neutral rating on shares of Fresenius Medical Care AG & Co. (NYSE:FMS) in a report issued on Friday morning.

Other research analysts also recently issued research reports about the company. Zacks Investment Research reaffirmed a hold rating on shares of Fresenius Medical Care AG & Co. in a research note on Tuesday, November 13th. TheStreet cut Fresenius Medical Care AG & Co. from a b- rating to a c+ rating in a research report on Monday, November 12th. Royal Bank of Canada reiterated a neutral rating on shares of Fresenius Medical Care AG & Co. in a research report on Wednesday, October 17th. UBS Group upgraded Fresenius Medical Care AG & Co. from a neutral rating to a buy rating and set a $82.00 price objective for the company in a research report on Friday, October 26th. Finally, ValuEngine cut Fresenius Medical Care AG & Co. from a hold rating to a sell rating in a research report on Wednesday, October 17th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $62.00.

Shares of NYSE:FMS traded down $3.56 during midday trading on Friday, hitting $35.67. 749,471 shares of the stock were exchanged, compared to its average volume of 266,389. The company has a market capitalization of $24.08 billion, a PE ratio of 16.14, a price-to-earnings-growth ratio of 1.82 and a beta of 1.10. The company has a quick ratio of 1.00, a current ratio of 1.24 and a debt-to-equity ratio of 0.41. Fresenius Medical Care AG & Co. has a twelve month low of $35.24 and a twelve month high of $57.94.

Fresenius Medical Care AG & Co. (NYSE:FMS) last released its quarterly earnings results on Tuesday, October 30th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.11. The business had revenue of $4.72 billion during the quarter. Fresenius Medical Care AG & Co. had a return on equity of 10.87% and a net margin of 11.71%. As a group, equities analysts anticipate that Fresenius Medical Care AG & Co. will post 2.41 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC purchased a new stake in Fresenius Medical Care AG & Co. in the 2nd quarter valued at about $106,000. Mount Yale Investment Advisors LLC purchased a new stake in Fresenius Medical Care AG & Co. in the 2nd quarter valued at about $192,000. HBK Sorce Advisory LLC purchased a new stake in Fresenius Medical Care AG & Co. in the 3rd quarter valued at about $209,000. Cibc Bank USA purchased a new stake in Fresenius Medical Care AG & Co. in the 3rd quarter valued at about $215,000. Finally, Sustainable Insight Capital Management LLC purchased a new stake in Fresenius Medical Care AG & Co. in the 3rd quarter valued at about $243,000. Institutional investors own 2.45% of the company’s stock.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co KGaA provides products and services for patients with chronic kidney failure. The company’s products include dialysis machines, dialyzers and related disposables. It also offers renal information technology solutions and provides services such as renal replacement therapy and therapeutic apheresis.

Further Reading: What does cost of debt say about a company’s financial health?

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply